



CUMBERLAND EMERGING TECHNOLOGIES APPOINTS SENIOR EXECUTIVES

(Nashville, Tenn.) September 22, 2005 - Cumberland Emerging Technologies (CET), a company which assists research institutions in bringing biomedical technologies and products to the marketplace, is pleased to announce the appointments of James P. Leyda, Ph.D. as Director of Corporate Development and Joseph O. Rolwing as Director of the CET Life Sciences Center.

Dr. Leyda has more than 40 years of experience in the pharmaceutical and biomedical industries. He began his career at Lederle Laboratories before moving to the Merrell and Hoechst Marion Roussel companies (now Aventis) where he served in a variety of leadership positions, overseeing marketing and regulatory matters, strategic research alliances, and new product development. Specifically, he was involved with the development and commercialization of such major pharmaceutical products as Seldane[®], Allegra[®], Citricel[®], Nicorette[®] and Nicoderm[®].



Most recently, Dr. Leyda served as president of Emerging Concepts, Inc., a Cincinnati-based company dedicated to the development of early-stage biomedical technologies. During his tenure, he secured more than \$12 million in grant funding. He holds an undergraduate degree in pharmacy from Ohio Northern University, and a master's and doctorate of pharmaceutical chemistry from The Ohio State University. At CET, he is responsible for furthering the organization's mission through strategic research alliances and federal grant funding.

-- more --

Prior to joining CET, Mr. Rolwing served as vice president and general manager of Genetics Associates, Inc., a \$3.2 million diagnostic medical lab. Earlier in his 30-year healthcare career he was vice president of corporate affairs for Centerstone Community Mental Health Centers, Inc., where he oversaw managed care contracting, budgeting, risk management and accounting. He earned an MBA from the University of North Carolina in Chapel Hill and an undergraduate degree from Southeast Missouri State University.



Mr. Rolwing oversees all aspects of the CET Life Sciences Center, which is adjacent to the Union Station Hotel and across from the Frist Center for the Visual Arts. Currently, the center has 8 tenants and is undergoing an expansion that will provide an additional 5,400 square feet of laboratory and research space.

“We are excited about the involvement of these two outstanding professionals,” said A.J. Kazimi, CET’s Chief Executive Officer. “Both individuals bring significant knowledge and experience essential to advancing CET’s mission of developing medicines and technologies that address a medical need and making them commercially available to those can benefit.”

Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc. and the Tennessee Technology Development Corporation. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the commercial marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products.

* * *